An Evaluation of Losmapimod in patients with Chronic Obstructive Pulmonary Disease (COPD) with systemic inflammation stratified using fibrinogen (EVOLUTION)
Latest Information Update: 07 Sep 2023
Price :
$35 *
At a glance
- Drugs Losmapimod (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms EVOLUTION
- 18 May 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 18 May 2016 Primary endpoint has not been met. (Endothelial function as measured by flow mediated dilatation), as per results presented at the 112th International Conference of the American Thoracic Society.
- 18 May 2016 Primary endpoint has not been met. (Vascular inflammation on FDG PET-CT), as per results presented at the 112th International Conference of the American Thoracic Society.